SDI Review Form 1.6

Journal Name:	**International Journal of Biochemistry Research & Review**
Manuscript Number:	**2014_IJBcRR_11870**
Title of the Manuscript:	**Arginase as a new cardiac marker for diagnosis of coronary artery disease**
Type of the Article	**Original Research Article**

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments	**1. Authors must declare what there are measured! Arginase activity or arginase level. As shown the reference number 7, it is arginase activity. Therefore authors write all the "arginase/ arginase level" terms as "arginase level". Title included.** **2. Introduction is too long, but explains the hypothesis and aim, clearly.** **Authors must added a figure legend for Fig 1., separately.** **In lane 46. Please write Fig.1 as (Fig1).** **3. Materials and Methods:** **Please write the inclusion and exclusion in text as sentences.** **Authors must declare the inclusion and exclusion criteria also for the control group.** **Authors measure only CK-MB, AST and arginase activities. Therefore it is better to explain the methods in detailed form in materials methods section.** **Authors must explain the statistical methods.** **4. Results and Discussion** **Firstly it is better when results and discussion sections are separated** **Authors must explain the demographic and anthropometric results in a table or in text of results.** **Authors must explain the medications from UA and MI groups, if use the control group, also in control group.**	1. Arginase activity was measured and not levels. 2.Correction done 3.Correction done 4.Correction done

	Authors must write the results in detailed form. **The significance of the results is not clear. It is significant than control group or UA group, or both?** **As shown in lane 96, is this result from this research? But a reference number (reference 7) is given. If a relationship between your results and reference no 7 please discuss it in "discussion section". Additionally reference 8, 9, 10,11 and 12 (lane 98).** **Authors declare in lane 105,106 a strong correlation, please write the correlation details. For example correlation coefficient, OR, etc.** **Discussion must be written in a more detailed and explanatory form.** **Measurements of AST, CK-MB and arginase activities cannot explain the severity of a marker. For this explanation authors must use ROC curves, and calculations for sensitivity and specifity.**	
Minor REVISION comments	If there any ethical issue	
Optional/General comments	**There are some misspellings. Authors must correct it.** **I think it needs a substantial revision and re-writing.**	